Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.
Akiko MitaMaiko AbumiyaMasatomo MiuraTakenori NiiokaSaori TakahashiTomoko YoshiokaYoshihiro KameokaNaoto TakahashiPublished in: Experimental hematology & oncology (2018)
The DE regimen was better suited to avoid treatment interruption. The daily dose of bosutinib might be adjusted based on target C0 to avoid adverse events by therapeutic drug monitoring in general practice.